Latest Pluristem Therapeutics (PSTI) Headlines
Preclinical Results for Pluristem's PLX-PAD Cells in Tendon Injury Presented at American Academy of Orthopedic Surgeons' Annual Meeting
GlobeNewswire - Wed Mar 12, 3:00AM CDT
Pluristem Therapeutics, Inc. (Nasdaq
STI) (TASE LTR), a leading developer of placenta-based cell therapies, today announced that Dr. Scott Rodeo of New York's Hospital for Special Surgery (HSS) presented his research findings in a scientific poster titled, "Use of Human Placental-Derived Adherent Stromal Cells Improves Tendon Healing in a Preclinical Model of Tendon Injury," at the American Academy of Orthopedic Surgeons' (AAOS) Annual Meeting, on March 11-15 in New Orleans.
Appointments, Financial Reports, and FDA Approvals - Analyst Notes on Hospira, Karyopharm, Revance, Pluristem, and Sunesis
PR Newswire - Tue Mar 11, 8:19AM CDT
Today, Analysts Review released its analysts' notes regarding Hospira Inc. (NYSE: HSP), Karyopharm Therapeutics, Inc. (NASDAQ: KPTI), Revance Therapeutics, Inc. (NASDAQ: RVNC), Pluristem Therapeutics, Inc. (NASDAQ: PSTI), and Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Pluristem to Present at Barclays and RegenMed Financial Conferences
GlobeNewswire - Tue Mar 11, 2:59AM CDT
Pluristem Therapeutics, Inc. (Nasdaq STI) (TASE LTR), a leading developer of placenta-based cell therapies, today announced that Company executives will present at two upcoming financial conferences:
Global Stem Cell Umbilical Cord Blood (UCB) Market to 2020
M2 - Mon Mar 10, 7:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gsw6jj/global_stem_cell) has announced the addition of the "Global Stem Cell Umbilical Cord Blood (UCB) Market to 2020" report to their offering. The market is expected to reach revenue of $56.4 billion by 2020, growing at CAGR of 33.4% during 2013 to 2020 The study observed that the global umbilical cord blood stem cell market is forecasted to reach market value over $11.5 billion in 2014 from $ 6.5 billion in 2012. Developments and approvals for novel cord blood stem cells therapies is expected to drive the market growth. The storage service market was valued at $7.4 billion in 2013. Increase in prevalence rate of chronic diseases such as cancer, diabetes, blood disease, immune disease, metabolic disease etc. has increased the need of cost effective and efficient way of treatment. However, cord blood stem cells have the potential to treat these chronic diseases effectively. These stem cells have special property of higher cell count in lower blood volume. Collection of these stem cells is much easier than other stem cells and could be stored in specialized preservation facilities called as Cord Blood Stem Cell Banks.Cord blood stem cells market is in its emerging phase. Significant applications of stem cells in the treatment of various disorders will be commercialized very soon as most of them are in the last phase of clinical trials. Patents for collection techniques and therapeutics methods are approved by respective government of developed countries however patents for UCB stem cells are comparatively less in developing economies. According to lead analyst Debbie Shields, the geographic analysis shows that the North American market for cord blood stem cell would account for approx. 44% of total revenue generated by the cord blood market in 2013. However, much expected growth is to occur in Asia-Pacific regions during the forecast period, because of growing demand for chronic disease treatments and widely increasing awareness levels. This report study offers updated review about major market players present in this market such as researcher based pharmaceutical companies and therapeutics services companies. Key Market Segments Global Stem cell UCB market by storage - Public cord blood banks - Private cord blood banks - Public Vs. Private UCB banks Global Stem cell UCB market by Diseases - Cancer/ Oncology diseases - Acute Leukemia - Chronic Leukemia - High Risk Solid Tumors - Myelodysplastic Syndrome - Blood diseases - Aplastic Anemia - Beta Thalassemia - Sickle Cell disease - Immune Disorders - Leukocyte Adhesion Deficiency - Hystiocytic Disorders - Wiskott-Aldrich - Metabolic Disorders - Krabbe Disease - Hurler Syndrome - Sanfilippo Syndrome - Other diseases - Osteopetrosis - Hemophagoyticlymphohistiocytosis Global Stem cell UCB market by Technology - Stem Cell Transplant - Autologous transplant - Allogenic transplant - Transplant Medicine - Regenerative Medicine - Others - Cord Blood Banking - Blood Transfusion - Cell Based Genetics Companies Mentioned - Advanced Cell Technology Inc. (USA) - Athersys Inc. - California Stem Cell - Cytori Therapeutics Inc. - Geron Corporation - Mesoblast Limited - NeoStem Inc. - Opexa Therapeutics Inc. - Osiris Therapeutics - Pluristem Therapeutics Inc. For more information visit http://www.researchandmarkets.com/research/gs..._stem_cell
Pluristem CEO Zami Aberman to Present on Cell & Gene Therapy Panel Discussion at BIO-Europe Spring 2014
GlobeNewswire - Fri Mar 07, 9:45AM CST
Pluristem Therapeutics, Inc. (Nasdaq STI) (TASE LTR), a leading developer of placenta-based cell therapies, today announced the Company's Chief Executive Officer Zami Aberman will deliver a brief presentation and be a panelist at BIO-Europe Spring 2014 on March 10, 2014 at 4pm. BIO-Europe Spring 2014 will take place on March 10-12 in Turin, Italy.
Top Stories in Biotech This Morning: Pluristem Therapeutics, Inc, Rigel Pharmaceuticals, Inc. and Sa
George Budwell, The Motley Fool - Motley Fool - Thu Mar 06, 7:49AM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Let's take a look at the top stories in biotech and health...
US FDA Approves Pluristem's Commercial Scale Cell Manufacturing Process
GlobeNewswire - Thu Mar 06, 2:00AM CST
Pluristem Therapeutics, Inc. (Nasdaq STI) (TASE LTR), a leading developer of placenta-based cell therapies, today announced that the United States Food and Drug Administration (FDA) has reviewed Pluristem's comparability studies of its PLacental eXpanded (PLX) cell products and granted approval for the Company to manufacture these products in its new commercial-scale cell manufacturing facility.
Narus nSystem Helps Enterprises Accelerate Time to Resolution of Cyber Threats and Build "Zero Trust" Networks
Marketwire - Tue Feb 25, 8:30AM CST
(RSA Conference, Booth #2715) -- Narus, Inc., a leader in big data analytics for cybersecurity solutions, today announced the next generation of Narus nSystem. The new release accelerates the time it takes to resolve cyber threats by delivering visualizations that give security teams the context to understand data intuitively and to discover previously unknown threats. With the ability to integrate into existing infrastructure, Narus nSystem enables organizations to build "zero trust" networks and take a proactive approach to cybersecurity.
Pipeline Progress at Pluristem - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 24, 4:50PM CST
Pluristem recently announced that it has submitted its application to the U.S. Food and Drug Administration (FDA) to grant orphan drug designation to its PLX-PAD cells for the treatment of severe preeclampsia.
Bone Marrow Transplantation - Pipeline Review, H1 2014 Research Report
M2 - Mon Feb 24, 3:47AM CST
Research and Markets (http://www.researchandmarkets.com/research/f8glf8/bone_marrow) has announced the addition of the "Bone Marrow Transplantation - Pipeline Review, H1 2014" report to their offering. 'Bone Marrow Transplantation - Pipeline Review, H1 2014', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Bone Marrow Transplantation, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Bone Marrow Transplantation. Scope - A snapshot of the global therapeutic scenario for Bone Marrow Transplantation. - A review of the Bone Marrow Transplantation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Bone Marrow Transplantation pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: List of Tables List of Figures Introduction Bone Marrow Transplantation Overview Therapeutics Development Late Stage Products Clinical Stage Products Early Stage Products Bone Marrow Transplantation - Therapeutics Assessment Drug Profiles Allogeneic MPC For Bone Marrow Transplantation - Drug Profile melphalan - Drug Profile TM-400 - Drug Profile PLX-BMP - Drug Profile CBLB-612 - Drug Profile CBLB-612 - Drug Profile Perforin Inhibitor - Drug Profile R&D Progress Featured News & Press Releases Appendix List of Tables List of Figures Companies Mentioned Mesoblast Limited Cleveland BioLabs, Inc. Pluristem Therapeutics Inc. Spectrum Pharmaceuticals, Inc. TikoMed AB For more information visit http://www.researchandmarkets.com/research/f8...one_marrow About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Pluristem Therapeutics Granted New Patent amid Positive Clinical Trial
ACCESSWIRE - Fri Feb 21, 9:54AM CST
Granted New Patent
Pluristem Submits FDA Orphan Drug Application for Preeclampsia
GlobeNewswire - Thu Feb 20, 2:00AM CST
Pluristem Therapeutics, Inc. (Nasdaq STI) (TASE LTR), a leading developer of placenta-based cell therapies, today announced it is submitting its application to the United Stated Food and Drug Administration requesting the Company to be granted Orphan Drug Designation for its PLacental eXpanded (PLX-PAD) cells in the treatment of severe preeclampsia.
Pluristem Therapeutics Inc awarded key 3D Cell patent in Australia for placental or fat cells
M2 - Tue Feb 18, 4:57AM CST
Cell therapies company Pluristem Therapeutics Inc (NasdaqCM STI) (TASE LTR) reported on Tuesday the receipt of a new patent, the patent #2007228341, from the Australian Patent Office.
Pluristem Receives Key 3D Cell Expansion Patent in Australia
GlobeNewswire - Tue Feb 18, 2:00AM CST
Pluristem Therapeutics, Inc. (Nasdaq STI) (TASE LTR), a leading developer of placenta-based cell therapies, today announced it has been granted a new patent by the Australian Patent Office. Patent #2007228341 covers the method and composition of matter for three-dimensional (3D) expansion of placental or adipose (fat) stromal cells, Pluristem's key technology platform. Patent claims also include methods of treatment using placental cells for numerous diseases including graft vs. host disease (GvHD), heart disease, stroke, burns, loss of tissue, loss of blood, anemia, and autoimmune disorders. Patents with similar claims have also been granted to Pluristem in Russia and in South Africa. This marks Pluristem's third patent issued in Australia and its 28th patent issued worldwide.
Aplastic Anemia - Pipeline Review, H2 2013 Research Report Available Now
M2 - Fri Feb 14, 3:02AM CST
Research and Markets (http://www.researchandmarkets.com/research/ntpg62/aplastic_anemia) has announced the addition of the "Aplastic Anemia - Pipeline Review, H2 2013" report to their offering. 'Aplastic Anemia - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Aplastic Anemia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Aplastic Anemia. Scope - A snapshot of the global therapeutic scenario for Aplastic Anemia. - A review of the Aplastic Anemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Aplastic Anemia pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: List of Tables List of Figures Introduction Aplastic Anemia Overview Therapeutics Development Pipeline Products for Aplastic Anemia - Overview Pipeline Products for Aplastic Anemia - Comparative Analysis Aplastic Anemia - Therapeutics under Development by Companies Aplastic Anemia - Therapeutics under Investigation by Universities/Institutes Aplastic Anemia - Pipeline Products Glance Clinical Stage Products Early Stage Products Aplastic Anemia - Products under Development by Companies Aplastic Anemia - Products under Investigation by Universities/Institutes Aplastic Anemia - Companies Involved in Therapeutics Development Aplastic Anemia - Therapeutics Assessment Drug Profiles eltrombopag olamine - Drug Profile HemaXellerate - Drug Profile darbepoetin alfa biosimilar - Drug Profile PLX Cells for Aplastic Bone Marrow - Drug Profile Immunotoxins - Drug Profile Aplastic Anemia - Recent Pipeline Updates Aplastic Anemia - Dormant Projects Aplastic Anemia - Product Development Milestones Featured News & Press Releases Appendix List of Tables List of Figures Companies Mentioned GlaxoSmithKline plc Bio-Matrix Scientific Group, Inc. Pluristem Therapeutics Inc. Aprogen, Inc. For more information visit http://www.researchandmarkets.com/research/nt...tic_anemia About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Akpabio - No Apology for Supporting Jonathan [interview]
All Africa Global Media - Thu Feb 13, 4:36AM CST
The Akwa Ibom State Governor, Godswill Akpabio, after paying a courtesy call on the National Chairman of the Peoples Democratic Party, Adamu Mu'azu, pledged his support to the new authority. Chuks Okocha presents excerpts of the session
Pluristem CEO Zami Aberman to Speak on Panel at 9th Annual Stem Cell Summit on February 18, 2014
GlobeNewswire - Thu Feb 13, 2:00AM CST
Pluristem Therapeutics, Inc. (Nasdaq STI) (TASE LTR), a leading developer of placenta-based cell therapies, today announced that its CEO and Chairman, Zami Aberman, will be a speaker on a panel titled, "Disrupting the Pharma Model with Allogeneic Stem Cell Therapies - Part I" at the 9th Annual Stem Cell Summit. The summit will take place in New York on Tuesday, February 18, 2014.
Medical Key Opinion Leaders in Preeclampsia Join Pluristem's Steering Committee
GlobeNewswire - Tue Feb 11, 2:00AM CST
Pluristem Therapeutics, Inc. (Nasdaq STI) (TASE LTR), a leading developer of placenta-based cell therapies, today announced it has formed a Preeclampsia Steering Committee to advance its PLacental eXpanded (PLX) cell therapies for the treatment of preeclampsia.
Will Regeneron (REGN) Disappoint in Q4? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 10, 3:30PM CST
Regeneron is set to report its fourth quarter 2013 results on Feb 11 before the opening bell.
Company news for February 05, 2014 - Corporate Summary
Zacks Equity Research - Zacks Investment Research - Wed Feb 05, 9:06AM CST
Companies in the News are: FURX,MSFT,ATMI,PSTI
Preclinical Results for Pluristem's PLX-PAD Cells in Tendon Injury Presented at American Academy of Orthopedic Surgeons' Annual Meeting
GlobeNewswire - Wed Mar 12, 3:00AM CDT
Pluristem Therapeutics, Inc. (Nasdaq
STI) (TASE LTR), a leading developer of placenta-based cell therapies, today announced that Dr. Scott Rodeo of New York's Hospital for Special Surgery (HSS) presented his research findings in a scientific poster titled, "Use of Human Placental-Derived Adherent Stromal Cells Improves Tendon Healing in a Preclinical Model of Tendon Injury," at the American Academy of Orthopedic Surgeons' (AAOS) Annual Meeting, on March 11-15 in New Orleans. Appointments, Financial Reports, and FDA Approvals - Analyst Notes on Hospira, Karyopharm, Revance, Pluristem, and Sunesis
PR Newswire - Tue Mar 11, 8:19AM CDT
Today, Analysts Review released its analysts' notes regarding Hospira Inc. (NYSE: HSP), Karyopharm Therapeutics, Inc. (NASDAQ: KPTI), Revance Therapeutics, Inc. (NASDAQ: RVNC), Pluristem Therapeutics, Inc. (NASDAQ: PSTI), and Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Pluristem to Present at Barclays and RegenMed Financial Conferences
GlobeNewswire - Tue Mar 11, 2:59AM CDT
Pluristem Therapeutics, Inc. (Nasdaq
STI) (TASE LTR), a leading developer of placenta-based cell therapies, today announced that Company executives will present at two upcoming financial conferences: Global Stem Cell Umbilical Cord Blood (UCB) Market to 2020
M2 - Mon Mar 10, 7:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gsw6jj/global_stem_cell) has announced the addition of the "Global Stem Cell Umbilical Cord Blood (UCB) Market to 2020" report to their offering. The market is expected to reach revenue of $56.4 billion by 2020, growing at CAGR of 33.4% during 2013 to 2020 The study observed that the global umbilical cord blood stem cell market is forecasted to reach market value over $11.5 billion in 2014 from $ 6.5 billion in 2012. Developments and approvals for novel cord blood stem cells therapies is expected to drive the market growth. The storage service market was valued at $7.4 billion in 2013. Increase in prevalence rate of chronic diseases such as cancer, diabetes, blood disease, immune disease, metabolic disease etc. has increased the need of cost effective and efficient way of treatment. However, cord blood stem cells have the potential to treat these chronic diseases effectively. These stem cells have special property of higher cell count in lower blood volume. Collection of these stem cells is much easier than other stem cells and could be stored in specialized preservation facilities called as Cord Blood Stem Cell Banks.Cord blood stem cells market is in its emerging phase. Significant applications of stem cells in the treatment of various disorders will be commercialized very soon as most of them are in the last phase of clinical trials. Patents for collection techniques and therapeutics methods are approved by respective government of developed countries however patents for UCB stem cells are comparatively less in developing economies. According to lead analyst Debbie Shields, the geographic analysis shows that the North American market for cord blood stem cell would account for approx. 44% of total revenue generated by the cord blood market in 2013. However, much expected growth is to occur in Asia-Pacific regions during the forecast period, because of growing demand for chronic disease treatments and widely increasing awareness levels. This report study offers updated review about major market players present in this market such as researcher based pharmaceutical companies and therapeutics services companies. Key Market Segments Global Stem cell UCB market by storage - Public cord blood banks - Private cord blood banks - Public Vs. Private UCB banks Global Stem cell UCB market by Diseases - Cancer/ Oncology diseases - Acute Leukemia - Chronic Leukemia - High Risk Solid Tumors - Myelodysplastic Syndrome - Blood diseases - Aplastic Anemia - Beta Thalassemia - Sickle Cell disease - Immune Disorders - Leukocyte Adhesion Deficiency - Hystiocytic Disorders - Wiskott-Aldrich - Metabolic Disorders - Krabbe Disease - Hurler Syndrome - Sanfilippo Syndrome - Other diseases - Osteopetrosis - Hemophagoyticlymphohistiocytosis Global Stem cell UCB market by Technology - Stem Cell Transplant - Autologous transplant - Allogenic transplant - Transplant Medicine - Regenerative Medicine - Others - Cord Blood Banking - Blood Transfusion - Cell Based Genetics Companies Mentioned - Advanced Cell Technology Inc. (USA) - Athersys Inc. - California Stem Cell - Cytori Therapeutics Inc. - Geron Corporation - Mesoblast Limited - NeoStem Inc. - Opexa Therapeutics Inc. - Osiris Therapeutics - Pluristem Therapeutics Inc. For more information visit http://www.researchandmarkets.com/research/gs..._stem_cell
Pluristem CEO Zami Aberman to Present on Cell & Gene Therapy Panel Discussion at BIO-Europe Spring 2014
GlobeNewswire - Fri Mar 07, 9:45AM CST
Pluristem Therapeutics, Inc. (Nasdaq
STI) (TASE LTR), a leading developer of placenta-based cell therapies, today announced the Company's Chief Executive Officer Zami Aberman will deliver a brief presentation and be a panelist at BIO-Europe Spring 2014 on March 10, 2014 at 4pm. BIO-Europe Spring 2014 will take place on March 10-12 in Turin, Italy. Top Stories in Biotech This Morning: Pluristem Therapeutics, Inc, Rigel Pharmaceuticals, Inc. and Sa
George Budwell, The Motley Fool - Motley Fool - Thu Mar 06, 7:49AM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Let's take a look at the top stories in biotech and health...
US FDA Approves Pluristem's Commercial Scale Cell Manufacturing Process
GlobeNewswire - Thu Mar 06, 2:00AM CST
Pluristem Therapeutics, Inc. (Nasdaq
STI) (TASE LTR), a leading developer of placenta-based cell therapies, today announced that the United States Food and Drug Administration (FDA) has reviewed Pluristem's comparability studies of its PLacental eXpanded (PLX) cell products and granted approval for the Company to manufacture these products in its new commercial-scale cell manufacturing facility. Narus nSystem Helps Enterprises Accelerate Time to Resolution of Cyber Threats and Build "Zero Trust" Networks
Marketwire - Tue Feb 25, 8:30AM CST
(RSA Conference, Booth #2715) -- Narus, Inc., a leader in big data analytics for cybersecurity solutions, today announced the next generation of Narus nSystem. The new release accelerates the time it takes to resolve cyber threats by delivering visualizations that give security teams the context to understand data intuitively and to discover previously unknown threats. With the ability to integrate into existing infrastructure, Narus nSystem enables organizations to build "zero trust" networks and take a proactive approach to cybersecurity.
Pipeline Progress at Pluristem - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 24, 4:50PM CST
Pluristem recently announced that it has submitted its application to the U.S. Food and Drug Administration (FDA) to grant orphan drug designation to its PLX-PAD cells for the treatment of severe preeclampsia.
Bone Marrow Transplantation - Pipeline Review, H1 2014 Research Report
M2 - Mon Feb 24, 3:47AM CST
Research and Markets (http://www.researchandmarkets.com/research/f8glf8/bone_marrow) has announced the addition of the "Bone Marrow Transplantation - Pipeline Review, H1 2014" report to their offering. 'Bone Marrow Transplantation - Pipeline Review, H1 2014', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Bone Marrow Transplantation, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Bone Marrow Transplantation. Scope - A snapshot of the global therapeutic scenario for Bone Marrow Transplantation. - A review of the Bone Marrow Transplantation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Bone Marrow Transplantation pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: List of Tables List of Figures Introduction Bone Marrow Transplantation Overview Therapeutics Development Late Stage Products Clinical Stage Products Early Stage Products Bone Marrow Transplantation - Therapeutics Assessment Drug Profiles Allogeneic MPC For Bone Marrow Transplantation - Drug Profile melphalan - Drug Profile TM-400 - Drug Profile PLX-BMP - Drug Profile CBLB-612 - Drug Profile CBLB-612 - Drug Profile Perforin Inhibitor - Drug Profile R&D Progress Featured News & Press Releases Appendix List of Tables List of Figures Companies Mentioned Mesoblast Limited Cleveland BioLabs, Inc. Pluristem Therapeutics Inc. Spectrum Pharmaceuticals, Inc. TikoMed AB For more information visit http://www.researchandmarkets.com/research/f8...one_marrow About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Pluristem Therapeutics Granted New Patent amid Positive Clinical Trial
ACCESSWIRE - Fri Feb 21, 9:54AM CST
Granted New Patent
Pluristem Submits FDA Orphan Drug Application for Preeclampsia
GlobeNewswire - Thu Feb 20, 2:00AM CST
Pluristem Therapeutics, Inc. (Nasdaq
STI) (TASE LTR), a leading developer of placenta-based cell therapies, today announced it is submitting its application to the United Stated Food and Drug Administration requesting the Company to be granted Orphan Drug Designation for its PLacental eXpanded (PLX-PAD) cells in the treatment of severe preeclampsia. Pluristem Therapeutics Inc awarded key 3D Cell patent in Australia for placental or fat cells
M2 - Tue Feb 18, 4:57AM CST
Cell therapies company Pluristem Therapeutics Inc (NasdaqCM
STI) (TASE LTR) reported on Tuesday the receipt of a new patent, the patent #2007228341, from the Australian Patent Office. Pluristem Receives Key 3D Cell Expansion Patent in Australia
GlobeNewswire - Tue Feb 18, 2:00AM CST
Pluristem Therapeutics, Inc. (Nasdaq
STI) (TASE LTR), a leading developer of placenta-based cell therapies, today announced it has been granted a new patent by the Australian Patent Office. Patent #2007228341 covers the method and composition of matter for three-dimensional (3D) expansion of placental or adipose (fat) stromal cells, Pluristem's key technology platform. Patent claims also include methods of treatment using placental cells for numerous diseases including graft vs. host disease (GvHD), heart disease, stroke, burns, loss of tissue, loss of blood, anemia, and autoimmune disorders. Patents with similar claims have also been granted to Pluristem in Russia and in South Africa. This marks Pluristem's third patent issued in Australia and its 28th patent issued worldwide. Aplastic Anemia - Pipeline Review, H2 2013 Research Report Available Now
M2 - Fri Feb 14, 3:02AM CST
Research and Markets (http://www.researchandmarkets.com/research/ntpg62/aplastic_anemia) has announced the addition of the "Aplastic Anemia - Pipeline Review, H2 2013" report to their offering. 'Aplastic Anemia - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Aplastic Anemia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Aplastic Anemia. Scope - A snapshot of the global therapeutic scenario for Aplastic Anemia. - A review of the Aplastic Anemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Aplastic Anemia pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: List of Tables List of Figures Introduction Aplastic Anemia Overview Therapeutics Development Pipeline Products for Aplastic Anemia - Overview Pipeline Products for Aplastic Anemia - Comparative Analysis Aplastic Anemia - Therapeutics under Development by Companies Aplastic Anemia - Therapeutics under Investigation by Universities/Institutes Aplastic Anemia - Pipeline Products Glance Clinical Stage Products Early Stage Products Aplastic Anemia - Products under Development by Companies Aplastic Anemia - Products under Investigation by Universities/Institutes Aplastic Anemia - Companies Involved in Therapeutics Development Aplastic Anemia - Therapeutics Assessment Drug Profiles eltrombopag olamine - Drug Profile HemaXellerate - Drug Profile darbepoetin alfa biosimilar - Drug Profile PLX Cells for Aplastic Bone Marrow - Drug Profile Immunotoxins - Drug Profile Aplastic Anemia - Recent Pipeline Updates Aplastic Anemia - Dormant Projects Aplastic Anemia - Product Development Milestones Featured News & Press Releases Appendix List of Tables List of Figures Companies Mentioned GlaxoSmithKline plc Bio-Matrix Scientific Group, Inc. Pluristem Therapeutics Inc. Aprogen, Inc. For more information visit http://www.researchandmarkets.com/research/nt...tic_anemia About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Akpabio - No Apology for Supporting Jonathan [interview]
All Africa Global Media - Thu Feb 13, 4:36AM CST
The Akwa Ibom State Governor, Godswill Akpabio, after paying a courtesy call on the National Chairman of the Peoples Democratic Party, Adamu Mu'azu, pledged his support to the new authority. Chuks Okocha presents excerpts of the session
Pluristem CEO Zami Aberman to Speak on Panel at 9th Annual Stem Cell Summit on February 18, 2014
GlobeNewswire - Thu Feb 13, 2:00AM CST
Pluristem Therapeutics, Inc. (Nasdaq
STI) (TASE LTR), a leading developer of placenta-based cell therapies, today announced that its CEO and Chairman, Zami Aberman, will be a speaker on a panel titled, "Disrupting the Pharma Model with Allogeneic Stem Cell Therapies - Part I" at the 9th Annual Stem Cell Summit. The summit will take place in New York on Tuesday, February 18, 2014. Medical Key Opinion Leaders in Preeclampsia Join Pluristem's Steering Committee
GlobeNewswire - Tue Feb 11, 2:00AM CST
Pluristem Therapeutics, Inc. (Nasdaq
STI) (TASE LTR), a leading developer of placenta-based cell therapies, today announced it has formed a Preeclampsia Steering Committee to advance its PLacental eXpanded (PLX) cell therapies for the treatment of preeclampsia. Will Regeneron (REGN) Disappoint in Q4? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 10, 3:30PM CST
Regeneron is set to report its fourth quarter 2013 results on Feb 11 before the opening bell.
Company news for February 05, 2014 - Corporate Summary
Zacks Equity Research - Zacks Investment Research - Wed Feb 05, 9:06AM CST
Companies in the News are: FURX,MSFT,ATMI,PSTI
